Short Interest in CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Rises By 35.8%

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) was the recipient of a large increase in short interest in February. As of February 13th, there was short interest totaling 41,351 shares, an increase of 35.8% from the January 29th total of 30,452 shares. Approximately 6.7% of the shares of the stock are sold short. Based on an average daily volume of 25,502 shares, the days-to-cover ratio is presently 1.6 days. Based on an average daily volume of 25,502 shares, the days-to-cover ratio is presently 1.6 days. Approximately 6.7% of the shares of the stock are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of CNS Pharmaceuticals in a research report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, CNS Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $20.00.

CNS Pharmaceuticals Trading Up 0.8%

NASDAQ:CNSP traded up $0.02 on Monday, hitting $3.13. The company had a trading volume of 2,996 shares, compared to its average volume of 46,439. CNS Pharmaceuticals has a 52 week low of $2.94 and a 52 week high of $55.20. The stock has a market capitalization of $1.94 million, a price-to-earnings ratio of -0.10 and a beta of 2.70. The firm has a 50 day moving average of $5.14 and a two-hundred day moving average of $6.66.

Institutional Investors Weigh In On CNS Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Armistice Capital LLC acquired a new position in CNS Pharmaceuticals in the 2nd quarter worth about $335,000. Boothbay Fund Management LLC bought a new stake in shares of CNS Pharmaceuticals during the fourth quarter worth about $71,000. Finally, Ikarian Capital LLC bought a new stake in shares of CNS Pharmaceuticals during the fourth quarter worth about $241,000. Institutional investors own 14.02% of the company’s stock.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.